Browsing: Homepage Slider
A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
In this new article published in Future Oncology, Ottoboni et al. report on the safety of a novel and recently FDA-approved polysorbate 80‒ and synthetic surfactant‒free intravenous formulation of the neurokinin 1 receptor antagonist aprepitant (HTX-019).
We have brought together our top takeaways from the five days of ASCO 2018.
In this opinion piece from our Editor, Jade Parker, you can discover the top 5 breast cancer advancements of 2017.